Inflammation in coronary artery disease

Cardiology in Review

Volumn 22, Issue 6, 2014, Pages 279-288

  Christodoulidis, Georgios ^a   Vittorio, Timothy J ^b   Fudim, Marat ^c   Lerakis, Stamatios ^d   Kosmas, Constantine E ^e  

^a WINTHROP UNIVERSITY HOSPITAL   (United States)

^b ST FRANCIS HOSPITAL   (United States)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Acute phase response; Atherosclerosis; Chemokines; Cytokines; Inflammatory markers; Pathogenesis; Proliferation

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CANAKINUMAB; COLCHICINE; INTERLEUKIN 1; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 8; METHOTREXATE; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA; ANTIINFLAMMATORY AGENT; CCL2 PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE;

ANTIGEN PRESENTATION; ANTIINFLAMMATORY ACTIVITY; CARDIOVASCULAR RISK; CELL DIFFERENTIATION; CELL PROLIFERATION; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; HUMAN; INFLAMMATION; META ANALYSIS (TOPIC); NEUTROPHIL CHEMOTAXIS; NONHUMAN; OUTCOME ASSESSMENT; PATHOGENESIS; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; ARTERITIS; METABOLISM; PHYSIOLOGY;

ANTI-INFLAMMATORY AGENTS; ARTERITIS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CHEMOKINE CCL2; CORONARY ARTERY DISEASE; HUMANS; INTERLEUKINS; RISK FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84927690721     PISSN: 10615377     EISSN: 15384683     Source Type: Journal    
DOI: 10.1097/CRD.0000000000000006     Document Type: Review

References (147)

1. Roger VL, Go AS, Lloyd-Jones DM, et al.; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Executive summary: heart disease and stroke statistics-2012 update: a report from the American Heart Association. Circulation. 2012; 125:188-197.
2. Enos WF, Holmes RH, Beyer J. Landmark article, July 18, 1953: Coronary disease among United States soldiers killed in action in Korea. Preliminary report. By William F. Enos, Robert H. Holmes and James Beyer. JAMA. 1986; 256:2859-2862.
3. O'Brien KD, Olin KL, Alpers C.E., et al. Comparison of apolipoprotein and proteoglycan deposits in human coronary atherosclerotic plaques: colocalization of biglycan with apolipoproteins. Circulation. 1998; 98:519-527.
4. Leitinger N. Oxidized phospholipids as modulators of inflammation in atherosclerosis. Curr Opin Lipidol. 2003; 14:421-430.
5. Skålén K, Gustafsson M, Rydberg EK, et al. Subendothelial retention of ath-erogenic lipoproteins in early atherosclerosis. Nature. 2002; 417:750-754.
6. Nakashima Y, Raines E W, Plump AS, et al. Upregulation of VCAM-1 and ICAM-1 at atherosclerosis-prone sites on the endothelium in the ApoE-deficient mouse. Arterioscler Thromb Vasc Biol. 1998; 18:842-851.
7. Cybulsky MI, Gimbrone MA Jr. Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. Science. 1991; 251:788-791.
8. Boring L, Gosling J, Cleary M., et al. Decreased lesion formation in CCR2-/-mice reveals a role for chemokines in the initiation of atherosclerosis. Nature. 1998; 394:894-897.
9. Gu L, Okada Y, Clinton S.K., et al. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol Cell. 1998; 2:275-281.
10. Smith JD, Trogan E, Ginsberg M., et al. Decreased atherosclerosis in mice deficient in both macrophage colony-stimulating factor (op) and apolipoprotein E. Proc Natl Acad Sci U S A. 1995; 92:8264-8268.
11. Peiser L, Mukhopadhyay S, Gordon S. Scavenger receptors in innate immunity. Curr Opin Immunol. 2002; 14:123-128.
12. Janeway CA Jr, Medzhitov R. Innate immune recognition. Annu Rev Immunol. 2002; 20:197-216.
13. Nicoletti A, Caligiuri G, Törnberg I, et al. The macrophage scavenger receptor type A directs modified proteins to antigen presentation. Eur J Immunol. 1999; 29:512-521.
14. Xu Q. Role of heat shock proteins in atherosclerosis. Arterioscler Thromb Vasc Biol. 2002; 22:1547-1559.
15. Miller YI, Chang MK, Binder C.J., et al. Oxidized low density lipoprotein and innate immune receptors. Curr Opin Lipidol. 2003; 14:437-445.
16. Björkbacka H, Kunjathoor V V, Moore KJ, et al. Reduced atherosclerosis in MyD88-null mice links elevated serum cholesterol levels to activation of innate immunity signaling pathways. Nat Med. 2004; 10:416-421.
17. Hansson GK. Immune mechanisms in atherosclerosis. Arterioscler Thromb Vasc Biol. 2001; 21:1876-1890.
18. Stemme S, Faber B, Holm J., et al. T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein. Proc Natl Acad Sci U S A. 1995; 92:3893-3897.
19. de Boer OJ, van der Wal AC, Houtkamp MA, et al. Unstable atherosclerotic plaques contain T-cells that respond to Chlamydia pneumoniae. Cardiovasc Res. 2000; 48:402-408.
20. Szabo SJ, Sullivan BM, Peng S.L., et al. Molecular mechanisms regulating Th1 immune responses. Annu Rev Immunol. 2003; 21:713-758.
21. Uyemura K, Demer LL, Castle S.C., et al. Cross-regulatory roles of interleukin (IL)-12 and IL-10 in atherosclerosis. J Clin Invest. 1996; 97:2130-2138.
22. Laurat E, Poirier B, Tupin E., et al. In vivo downregulation of T helper cell 1 immune responses reduces atherogenesis in apolipoprotein E-knockout mice. Circulation. 2001; 104:197-202.
23. Mallat Z, Corbaz A, Scoazec A., et al. Interleukin-18/interleukin-18 binding protein signaling modulates atherosclerotic lesion development and stability. Circ Res. 2001; 89:E41-E45.
24. Buono C, Binder CJ, Stavrakis G, et al. T-bet deficiency reduces atherosclerosis and alters plaque antigen-specific immune responses. Proc Natl Acad Sci U S A. 2005; 102:1596-1601.
25. Elhage R, Jawien J, Rudling M., et al. Reduced atherosclerosis in interleukin-18 deficient apolipoprotein E-knockout mice. Cardiovasc Res. 2003; 59:234-240.
26. Friesel R, Komoriya A, Maciag T. Inhibition of endothelial cell proliferation by gamma-interferon. J Cell Biol. 1987; 104:689-696.
27. Hansson GK, Hellstrand M, Rymo L., et al. Interferon gamma inhibits both proliferation and expression of differentiation-specific alpha-smooth muscle actin in arterial smooth muscle cells. J Exp Med. 1989; 170:1595-1608.
28. Amento EP, Ehsani N, Palmer H., et al. Cytokines and growth factors positively and negatively regulate interstitial collagen gene expression in human vascular smooth muscle cells. Arterioscler Thromb. 1991; 11:1223-1230.
29. Mach F, Schönbeck U, Bonnefoy J.Y., et al. Activation of monocyte/macrophage functions related to acute atheroma complication by ligation of CD40: induction of collagenase, stromelysin, and tissue factor. Circulation. 1997; 96:396-399.
30. Pinderski LJ, Fischbein M P, Subbanagounder G, et al. Overexpression of interleukin-10 by activated T lymphocytes inhibits atherosclerosis in LDL receptor-deficient mice by altering lymphocyte and macrophage phenotypes. Circ Res. 2002; 90:1064-1071.
31. Caligiuri G, Rudling M, Ollivier V., et al. Interleukin-10 deficiency increases atherosclerosis, thrombosis, and low-density lipoproteins in apolipoprotein E knockout mice. Mol Med. 2003; 9:10-17.
32. Robertson AK, Rudling M, Zhou X., et al. Disruption of TGF-beta signaling in T cells accelerates atherosclerosis. J Clin Invest. 2003; 112:1342-1350.
33. Shaw PX, Hörkkö S, Tsimikas S, et al. Human-derived anti-oxidized LDL autoantibody blocks uptake of oxidized LDL by macrophages and localizes to atherosclerotic lesions in vivo. Arterioscler Thromb Vasc Biol. 2001; 21:1333-1339.
34. Shaw PX, Hörkkö S, Chang MK, et al. Natural antibodies with the T15 idiot-ype may act in atherosclerosis, apoptotic clearance, and protective immunity. J Clin Invest. 2000; 105:1731-1740.
35. Binder CJ, Hörkkö S, Dewan A, et al. Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between Streptococcus pneumoniae and oxidized LDL. Nat Med. 2003; 9:736-743.
36. Witztum JL. Splenic immunity and atherosclerosis: a glimpse into a novel paradigm? J Clin Invest. 2002; 109:721-724.
37. Ait-Oufella H, Herbin O, Bouaziz J.D., et al. B cell depletion reduces the development of atherosclerosis in mice. J Exp Med. 2010; 207:1579-1587.
38. Kyaw T, Tay C, Khan A., et al. Conventional B2 B cell depletion ameliorates whereas its adoptive transfer aggravates atherosclerosis. J Immunol. 2010; 185:4410-4419.
39. Chyu KY, Nilsson J, Shah PK. Immune mechanisms in atherosclerosis and potential for an atherosclerosis vaccine. Discov Med. 2011; 11:403-412.
40. Asanuma Y, Oeser A, Shintani A.K., et al. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N Engl J Med. 2003; 349:2407-2415.
41. Hak AE, Karlson E W, Feskanich D, et al. Systemic lupus erythematosus and the risk of cardiovascular disease: results from the nurses' health study. Arthritis Rheum. 2009; 61:1396-1402.
42. Lande R, Ganguly D, Facchinetti V., et al. Neutrophils activate plasmacytoid dendritic cells by releasing self-DNA-peptide complexes in systemic lupus erythematosus. Sci Transl Med. 2011; 3:73ra19.
43. Garcia-Romo GS, Caielli S, Vega B., et al. Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus. Sci Transl Med. 2011; 3:73ra20.
44. Lee PY, Li Y, Richards H.B., et al. Type I interferon as a novel risk factor for endothelial progenitor cell depletion and endothelial dysfunction in systemic lupus erythematosus. Arthritis Rheum. 2007; 56:3759-3769.
45. Denny MF, Thacker S, Mehta H., et al. Interferon-alpha promotes abnormal vasculogenesis in lupus: a potential pathway for premature atherosclerosis. Blood. 2007; 110:2907-2915.
46. Li J, Fu Q, Cui H., et al. Interferon-α priming promotes lipid uptake and macrophage-derived foam cell formation: a novel link between interferon-α and atherosclerosis in lupus. Arthritis Rheum. 2011; 63:492-502.
47. Huo Y, Ley KF. Role of platelets in the development of atherosclerosis. Trends Cardiovasc Med. 2004; 14:18-22.
48. Kolodgie FD, Burke A P, Farb A, et al. The thin-cap fibroatheroma: a type of vulnerable plaque: the major precursor lesion to acute coronary syndromes. Curr Opin Cardiol. 2001; 16:285-292.
49. Kolodgie FD, Virmani R, Burke A P, et al. Pathologic assessment of the vulnerable human coronary plaque. Heart. 2004; 90:1385-1391.
50. Libby P, Aikawa M. Stabilization of atherosclerotic plaques: new mechanisms and clinical targets. Nat Med. 2002; 8:1257-1262.
51. Nidorf SM, Eikelboom J W, Budgeon CA, et al. Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol. 2013; 61:404-410.
52. Cronstein BN. The mechanism of action of methotrexate. Rheum Dis Clin North Am. 1997; 23:739-755.
53. Marnell L, Mold C, Du Clos TW. C-reactive protein: ligands, receptors and role in inflammation. Clin Immunol. 2005; 117:104-111.
54. Arner P. The adipocyte in insulin resistance: key molecules and the impact of the thiazolidinediones. Trends Endocrinol Metab. 2003; 14:137-145.
55. Yudkin JS, Juhan-Vague I, Hawe E., et al.; HIFMECH Study Group. Low-grade inflammation may play a role in the etiology of the metabolic syndrome in patients with coronary heart disease: the HIFMECH study. Metabolism. 2004; 53:852-857.
56. Ridker PM, Cushman M, Stampfer M.J., et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997; 336:973-979.
57. Ridker PM, Buring JE, Shih J, et al. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation. 1998; 98:731-733.
58. Danesh J, Wheeler JG, Hirschfield G.M., et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004; 350:1387-1397.
59. Koenig W, Löwel H, Baumert J., et al. C-reactive protein modulates risk prediction based on the Framingham Score: implications for future risk assessment: results from a large cohort study in southern Germany. Circulation. 2004; 109:1349-1353.
60. Cushman M, Arnold AM, Psaty B.M., et al. C-reactive protein and the 10-year incidence of coronary heart disease in older men and women: the cardiovascular health study. Circulation. 2005; 112:25-31.
61. Wilson PW, Pencina M, Jacques P., et al. C-reactive protein and reclassification of cardiovascular risk in the Framingham Heart Study. Circ Cardiovasc Qual Outcomes. 2008; 1:92-97.
62. Kaptoge S, Di Angelantonio E, Pennells L, et al. C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med. 2012; 367:1310-1320.
63. Ridker PM, Glynn RJ, Hennekens CH. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation. 1998; 97:2007-2011.
64. Ridker PM, Hennekens CH, Buring J.E., et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000; 342:836-843.
65. Ridker PM, Rifai N, Rose L., et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002; 347:1557-1565.
66. Jones NR, Pegues MA, McCrory M.A., et al. A selective inhibitor of human C-reactive protein translation is efficacious in vitro and in Creactive protein transgenic mice and humans. Mol Ther Nucleic Acids. 2012; 1:e52.
67. Elliott P, Chambers JC, Zhang W, et al. Genetic Loci associated with C-reactive protein levels and risk of coronary heart disease. JAMA. 2009; 302:37-48.
68. Zacho J, Tybjaerg-Hansen A, Jensen J.S., et al. Genetically elevated C-reactive protein and ischemic vascular disease. N Engl J Med. 2008; 359:1897-1908.
69. Kaptoge S, Di Angelantonio E, Lowe G, et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet. 2010; 375:132-140.
70. Pearson TA, Mensah GA, Alexander R.W., et al.; Centers for Disease Control and Prevention; American Heart Association. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003; 107:499-511.
71. Downs JR, Clearfield M, Weis S., et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998; 279:1615-1622.
72. Ridker PM, Danielson E, Fonseca F.A., et al.; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008; 359:2195-2207.
73. Ridker PM, Morrow DA, Rose L.M., et al. Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipo-protein cholesterol <70 mg/dl and C-reactive protein <2 mg/l: an analysis of the PROVE-IT TIMI-22 trial. J Am Coll Cardiol. 2005; 45:1644-1648.
74. Cushing SD, Berliner JA, Valente A.J., et al. Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endo-thelial cells and smooth muscle cells. Proc Natl Acad Sci U S A. 1990; 87: 5134-5138.
75. Lutgens E, Faber B, Schapira K., et al. Gene profiling in atherosclerosis reveals a key role for small inducible cytokines: validation using a novel monocyte che-moattractant protein monoclonal antibody. Circulation. 2005; 111:3443-3452.
76. Ni W, Egashira K, Kitamoto S., et al. New anti-monocyte chemoattractant protein-1 gene therapy attenuates atherosclerosis in apolipoprotein E-knockout mice. Circulation. 2001; 103:2096-2101.
77. Frangogiannis NG. The mechanistic basis of infarct healing. Antioxid Redox Signal. 2006; 8:1907-1939.
78. Deo R, Khera A, McGuire D.K., et al. Association among plasma levels of monocyte chemoattractant protein-1, traditional cardiovascular risk factors, and subclinical atherosclerosis. J Am Coll Cardiol. 2004; 44:1812-1818.
79. de Lemos JA, Morrow DA, Sabatine M.S., et al. Association between plasma levels of monocyte chemoattractant protein-1 and long-term clinical outcomes in patients with acute coronary syndromes. Circulation. 2003; 107:690-695.
80. de Lemos JA, Morrow DA, Blazing M.A., et al. Serial measurement of mono-cyte chemoattractant protein-1 after acute coronary syndromes: results from the A to Z trial. J Am Coll Cardiol. 2007; 50:2117-2124.
81. Xu ZM, Zhao S P, Li QZ, et al. Atorvastatin reduces plasma MCP-1 in patients with acute coronary syndrome. Clin Chim Acta. 2003; 338:17-24.
82. Ohta H, Wada H, Niwa T., et al. Disruption of tumor necrosis factor-alpha gene diminishes the development of atherosclerosis in ApoE-deficient mice. Atherosclerosis. 2005; 180:11-17.
83. Zhang H, Park Y, Wu J., et al. Role of TNF-alpha in vascular dysfunction. Clin Sci (Lond). 2009; 116:219-230.
84. Grisar J, Aletaha D, Steiner C W, et al. Endothelial progenitor cells in active rheumatoid arthritis: effects of tumour necrosis factor and glucocorticoid therapy. Ann Rheum Dis. 2007; 66:1284-1288.
85. Hürlimann D, Forster A, Noll G., et al. Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis. Circulation. 2002; 106:2184-2187.
86. Irace C, Mancuso G, Fiaschi E., et al. Effect of anti TNF-alpha therapy on arterial diameter and wall shear stress and HDL cholesterol. Atherosclerosis. 2004; 177:113-118.
87. Sarén P, Welgus HG, Kovanen PT. TNF-alpha and IL-1beta selectively induce expression of 92-kDa gelatinase by human macrophages. J Immunol. 1996; 157:4159-4165.
88. Gebhard C, Stämpfi SF, Gebhard C.E., et al. Guggulsterone, an anti-inflammatory phytosterol, inhibits tissue factor and arterial thrombosis. Basic Res Cardiol. 2009; 104:285-294.
89. Jovinge S, Hamsten A, Tornvall P., et al. Evidence for a role of tumor necrosis factor alpha in disturbances of triglyceride and glucose metabolism predisposing to coronary heart disease. Metabolism. 1998; 47:113-118.
90. Jacobsson LT, Turesson C, Gülfe A, et al. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol. 2005; 32:1213-1218.
91. Dixon WG, Watson KD, Lunt M, et al.; British Society for Rheumatology Biologics Register Control Centre Consortium; British Society for Rheumatology Biologics Register. Reduction in the incidence of myo-cardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum. 2007; 56:2905-2912.
92. Dinarello CA. Proinflammatory cytokines. Chest. 2000; 118:503-508.
93. Dinarello CA. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood. 2011; 117:3720-3732.
94. Kirii H, Niwa T, Yamada Y., et al. Lack of interleukin-1beta decreases the severity of atherosclerosis in ApoE-deficient mice. Arterioscler Thromb Vasc Biol. 2003; 23:656-660.
95. Devlin CM, Kuriakose G, Hirsch E., et al. Genetic alterations of IL-1 receptor antagonist in mice affect plasma cholesterol level and foam cell lesion size. Proc Natl Acad Sci U S A. 2002; 99:6280-6285.
96. Waehre T, Yndestad A, Smith C., et al. Increased expression of interleukin-1 in coronary artery disease with downregulatory effects of HMG-CoA reduc-tase inhibitors. Circulation. 2004; 109:1966-1972.
97. Gaffen SL, Liu KD. Overview of interleukin-2 function, production and clinical applications. Cytokine. 2004; 28:109-123.
98. Katz MF, Farber H W, Dodds-Stitt Z, et al. Serotonin-stimulated aortic endo-thelial cells secrete a novel T lymphocyte chemotactic and growth factor. J Leukoc Biol. 1994; 55:567-573.
99. Upadhya S, Mooteri S, Peckham N., et al. Atherogenic effect of interleukin-2 and antiatherogenic effect of interleukin-2 antibody in apo-E-deficient mice. Angiology. 2004; 55:289-294.
100. Dinh TN, Kyaw TS, Kanellakis P, et al. Cytokine therapy with interleukin-2/anti-interleukin-2 monoclonal antibody complexes expands CD4+CD25+Foxp3+ regulatory T cells and attenuates development and progression of atherosclerosis. Circulation. 2012; 126:1256-1266.
101. Wadwa RP, Kinney GL, Ogden L, et al. Soluble interleukin-2 receptor as a marker for progression of coronary artery calcification in type 1 diabetes. Int J Biochem Cell Biol. 2006; 38:996-1003.
102. Lorenz MW, Markus HS, Bots M.L., et al. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation. 2007; 115:459-467.
103. Elkind MS, Rundek T, Sciacca R.R., et al. Interleukin-2 levels are associated with carotid artery intima-media thickness. Atherosclerosis. 2005; 180:181-187.
104. Mizia-Stec K, Gasior Z, Zahorska-Markiewicz B, et al. Serum tumour necrosis factor-alpha, interleukin-2 and interleukin-10 activation in stable angina and acute coronary syndromes. Coron Artery Dis. 2003; 14:431-438.
105. Simon AD, Yazdani S, Wang W., et al. Elevated plasma levels of interleukin-2 and soluble IL-2 receptor in ischemic heart disease. Clin Cardiol. 2001; 24:253-256.
106. Jones SA, Richards PJ, Scheller J, et al. IL-6 transsignaling: the in vivo consequences. J Interferon Cytokine Res. 2005; 25:241-253
107. Hartman J, Frishman WH: Inflammation and atherosclerosis: a review of the role of interleukin-6 in the development of atherosclerosis and the potential for targeted drug therapy. Cardiol in Ref 2014; 22:147-151.
108. Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol. 2006; 6:772-783.
109. Ogawa W, Kasuga M. Cell signaling. Fat stress and liver resistance. Science. 2008; 322:1483-1484.
110. Heinrich PC, Castell J V, Andus T. Interleukin-6 and the acute phase response. Biochem J. 1990; 265:621-636.
111. Le JM, Vilcek J. Interleukin 6: a multifunctional cytokine regulating immune reactions and the acute phase protein response. Lab Invest. 1989; 61:588-602.
112. Gruys E, Toussaint MJ, Niewold T.A., et al. Acute phase reaction and acute phase proteins. J Zhejiang Univ Sci B. 2005; 6:1045-1056.
113. Romano M, Sironi M, Toniatti C., et al. Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. Immunity. 1997; 6:315-325.
114. Hurst SM, Wilkinson TS, McLoughlin R.M., et al. Il-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation. Immunity. 2001; 14:705-714.
115. Brasier AR. The nuclear factor-kappaB-interleukin-6 signalling pathway mediating vascular inflammation. Cardiovasc Res. 2010; 86:211-218.
116. Wang Z, Castresana MR, Newman WH. NF-kappaB is required for TNF-alpha-directed smooth muscle cell migration. FEBS Lett. 2001; 508:360-364.
117. Wang D, Liu Z, Li Q., et al. An essential role for gp130 in neointima formation following arterial injury. Circ Res. 2007; 100:807-816.
118. Ikeda U, Ikeda M, Oohara T., et al. Interleukin 6 stimulates growth of vascular smooth muscle cells in a PDGF-dependent manner. Am J Physiol. 1991; 260(5 Pt 2):H1713-H1717.
119. Hernández-Presa M., Bustos C, Ortego M, et al. Angiotensin-converting enzyme inhibition prevents arterial nuclear factor-kappa B activation, monocyte chemoattractant protein-1 expression, and macrophage infiltration in a rabbit model of early accelerated atherosclerosis. Circulation. 1997; 95:1532-1541.
120. Wassmann S, Stumpf M, Strehlow K., et al. Interleukin-6 induces oxidative stress and endothelial dysfunction by overexpression of the angiotensin II type 1 receptor. Circ Res. 2004; 94:534-541.
121. Huber SA, Sakkinen P, Conze D., et al. Interleukin-6 exacerbates early atherosclerosis in mice. Arterioscler Thromb Vasc Biol. 1999; 19:2364-2367.
122. Schieffer B, Selle T, Hilfker A., et al. Impact of interleukin-6 on plaque development and morphology in experimental atherosclerosis. Circulation. 2004; 110:3493-3500.
123. Wallenius V, Wallenius K, Ahrén B, et al. Interleukin-6-deficient mice develop mature-onset obesity. Nat Med. 2002; 8:75-79.
124. Ridker PM, Rifai N, Stampfer M.J., et al. Plasma concentration of interleu-kin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation. 2000; 101:1767-1772.
125. Pai JK, Pischon T, Ma J., et al. Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med. 2004; 351:2599-2610.
126. Lindmark E, Diderholm E, Wallentin L., et al. Relationship between interleu-kin 6 and mortality in patients with unstable coronary artery disease: effects of an early invasive or noninvasive strategy. JAMA. 2001; 286:2107-2113.
127. Holmes WE, Lee J, Kuang W.J., et al. Structure and functional expression of a human interleukin-8 receptor. Science. 1991; 253:1278-1280.
128. Charo IF, Ransohoff RM. The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med. 2006; 354:610-621.
129. Rus HG, Vlaicu R, Niculescu F. Interleukin-6 and interleukin-8 protein and gene expression in human arterial atherosclerotic wall. Atherosclerosis. 1996; 127:263-271.
130. Apostolopoulos J, Davenport P, Tipping PG. Interleukin-8 production by macrophages from atheromatous plaques. Arterioscler Thromb Vasc Biol. 1996; 16:1007-1012.
131. Liu Y, Hultén LM, Wiklund O. Macrophages isolated from human atherosclerotic plaques produce IL-8, and oxysterols may have a regulatory function for IL-8 production. Arterioscler Thromb Vasc Biol. 1997; 17:317-323.
132. Dje N'Guessan P, Riediger F, Vardarova K, et al. Statins control oxidized LDL-mediated histone modifications and gene expression in cultured human endothelial cells. Arterioscler Thromb Vasc Biol. 2009; 29:380-386.
133. Ryoo SW, Kim DU, Won M, et al. Native LDL induces interleukin-8 expression via H2O2, p38 Kinase, and activator protein-1 in human aortic smooth muscle cells. Cardiovasc Res. 2004; 62:185-193.
134. Gerszten RE, Garcia-Zepeda EA, Lim Y.C., et al. MCP-1 and IL-8 trigger firm adhesion of monocytes to vascular endothelium under flow conditions. Nature. 1999; 398:718-723.
135. Yue TL, Wang X, Sung C P, et al. Interleukin-8. A mitogen and chemoattrac-tant for vascular smooth muscle cells. Circ Res. 1994; 75:1-7.
136. Moreau M, Brocheriou I, Petit L., et al. Interleukin-8 mediates downregulation of tissue inhibitor of metalloproteinase-1 expression in cholesterol-loaded human macrophages: relevance to stability of atherosclerotic plaque. Circulation. 1999; 99:420-426.
137. Simonini A, Moscucci M, Muller D.W., et al. IL-8 is an angiogenic factor in human coronary atherectomy tissue. Circulation. 2000; 101:1519-1526.
138. Boisvert WA, Santiago R, Curtiss L.K., et al. A leukocyte homologue of the IL-8 receptor CXCR-2 mediates the accumulation of macrophages in atherosclerotic lesions of LDL receptor-deficient mice. J Clin Invest. 1998; 101:353-363.
139. Kim CS, Park HS, Kawada T, et al. Circulating levels of MCP-1 and IL-8 are elevated in human obese subjects and associated with obesity-related parameters. Int J Obes (Lond). 2006; 30:1347-1355.
140. Trøseid M, Lappegård KT, Claudi T., et al. Exercise reduces plasma levels of the chemokines MCP-1 and IL-8 in subjects with the metabolic syndrome. Eur Heart J. 2004; 25:349-355.
141. Rezaie-Majd A, Maca T, Bucek R.A., et al. Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patients. Arterioscler Thromb Vasc Biol. 2002; 22:1194-1199.
142. Herder C, Baumert J, Thorand B., et al. Chemokines and incident coronary heart disease: results from the MONICA/KORA Augsburg case-cohort study, 1984-2002. Arterioscler Thromb Vasc Biol. 2006; 26:2147-2152.
143. Inoue T, Komoda H, Nonaka M., et al. Interleukin-8 as an independent predictor of long-term clinical outcome in patients with coronary artery disease. Int J Cardiol. 2008; 124:319-325.
144. Panichi V, Taccola D, Rizza G.M., et al. Interleukin-8 is a powerful prognostic predictor of all-cause and cardiovascular mortality in dialytic patients. Nephron Clin Pract. 2006; 102:c51-c58.
145. Romuk E, Skrzep-Poloczek B, Wojciechowska C., et al. Selectin-P and inter-leukin-8 plasma levels in coronary heart disease patients. Eur J Clin Invest. 2002; 32:657-661.
146. Hashmi S, Zeng QT. Role of interleukin-17 and interleukin-17-induced cyto-kines interleukin-6 and interleukin-8 in unstable coronary artery disease. Coron Artery Dis. 2006; 17:699-706.
147. Riesenberg K, Levy R, Katz A., et al. Neutrophil superoxide release and inter-leukin 8 in acute myocardial infarction: distinction between complicated and uncomplicated states. Eur J Clin Invest. 1997; 27:398-404.